These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37111340)

  • 1. Leveraging Hot Spots of TEAD-Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling.
    Zhao B; Pobbati AV; Rubin BP; Stauffer S
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex.
    Pobbati AV; Rubin BP
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33352993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive
    Nouri K; Azad T; Ling M; Janse van Rensburg HJ; Pipchuk A; Shen H; Hao Y; Zhang J; Yang X
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
    Mills KR; Misra J; Torabifard H
    J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
    Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
    Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
    Chapeau EA; Sansregret L; Galli GG; Chène P; Wartmann M; Mourikis TP; Jaaks P; Baltschukat S; Barbosa IAM; Bauer D; Brachmann SM; Delaunay C; Estadieu C; Faris JE; Furet P; Harlfinger S; Hueber A; Jiménez Núñez E; Kodack DP; Mandon E; Martin T; Mesrouze Y; Romanet V; Scheufler C; Sellner H; Stamm C; Sterker D; Tordella L; Hofmann F; Soldermann N; Schmelzle T
    Nat Cancer; 2024 Jul; 5(7):1102-1120. PubMed ID: 38565920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
    Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
    Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VGLL2 and TEAD1 fusion proteins drive YAP/TAZ-independent transcription and tumorigenesis by engaging p300.
    Guo S; Hu X; Cotton JL; Ma L; Li Q; Cui J; Wang Y; Thakare RP; Tao Z; Ip YT; Wu X; Wang J; Mao J
    bioRxiv; 2024 May; ():. PubMed ID: 38746415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors.
    Holden JK; Cunningham CN
    Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29558384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
    Miesfeld JB; Link BA
    Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment.
    Mokhtari RB; Ashayeri N; Baghaie L; Sambi M; Satari K; Baluch N; Bosykh DA; Szewczuk MR; Chakraborty S
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.
    Zhou W; Li Y; Song J; Li C
    Anal Biochem; 2019 Dec; 586():113413. PubMed ID: 31479631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
    Zagiel B; Melnyk P; Cotelle P
    Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
    Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
    Elife; 2022 Nov; 11():. PubMed ID: 36398861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.
    Fan M; Lu W; Che J; Kwiatkowski NP; Gao Y; Seo HS; Ficarro SB; Gokhale PC; Liu Y; Geffken EA; Lakhani J; Song K; Kuljanin M; Ji W; Jiang J; He Z; Tse J; Boghossian AS; Rees MG; Ronan MM; Roth JA; Mancias JD; Marto JA; Dhe-Paganon S; Zhang T; Gray NS
    Elife; 2022 Oct; 11():. PubMed ID: 36300789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
    Hagenbeek TJ; Zbieg JR; Hafner M; Mroue R; Lacap JA; Sodir NM; Noland CL; Afghani S; Kishore A; Bhat KP; Yao X; Schmidt S; Clausen S; Steffek M; Lee W; Beroza P; Martin S; Lin E; Fong R; Di Lello P; Kubala MH; Yang MN; Lau JT; Chan E; Arrazate A; An L; Levy E; Lorenzo MN; Lee HJ; Pham TH; Modrusan Z; Zang R; Chen YC; Kabza M; Ahmed M; Li J; Chang MT; Maddalo D; Evangelista M; Ye X; Crawford JJ; Dey A
    Nat Cancer; 2023 Jun; 4(6):812-828. PubMed ID: 37277530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YAP/TAZ-TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma.
    Papavassiliou KA; Sofianidi AA; Papavassiliou AG
    J Cell Mol Med; 2024 Apr; 28(8):e18330. PubMed ID: 38606782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity.
    Gridnev A; Maity S; Misra JR
    Front Oncol; 2022; 12():1021823. PubMed ID: 36523977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.